Cargando…

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors

BACKGROUND: Varlitinib is a highly potent, small-molecule, pan-HER inhibitor targeting HER1, HER2, and HER4. It has demonstrated activity in gastric, biliary tract, and breast cancers. OBJECTIVE: We conducted a phase Ib dose confirmation study to determine safety and early efficacy signals of varlit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Matilda Xinwei, Wong, Andrea L. A., Ow, Samuel, Sundar, Raghav, Tan, David S. P., Soo, Ross A., Chee, Cheng Ean, Lim, Joline S. J., Yong, Wei Peng, Lim, Siew Eng, Goh, Boon Cher, Wang, Lingzhi, Lee, Soo Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995271/ https://www.ncbi.nlm.nih.gov/pubmed/35195837 http://dx.doi.org/10.1007/s11523-022-00867-0

Ejemplares similares

Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells
por: Coelho, Sílvia Castro, et al.
Publicado: (2018)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy
por: Sundar, Raghav, et al.
Publicado: (2016)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma
por: Coelho, Sílvia Castro, et al.
Publicado: (2019)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
por: Neil, Alexander J., et al.
Publicado: (2023)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines
por: Dokduang, Hasaya, et al.
Publicado: (2020)

Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
por: Choo, Joan R. E., et al.
Publicado: (2022)

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer
por: Wong, Andrea L.A., et al.
Publicado: (2016)

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
por: Low, Jia Li, et al.
Publicado: (2022)

Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
por: Loh, Jerold, et al.
Publicado: (2023)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
por: Schöffski, Patrick, et al.
Publicado: (2018)

Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study
por: Sundar, Raghav, et al.
Publicado: (2017)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
por: Huang, Liang, et al.
Publicado: (2015)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours
por: Soo, Ross Andrew, et al.
Publicado: (2016)

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)
por: Javle, M.M., et al.
Publicado: (2021)

Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
por: Ding, Jinhua, et al.
Publicado: (2017)

PO-1174 3-weekly paclitaxel-carboplatin with radiation for stage III NSCLC – option during COVID-19 pandemic
por: Wong, H., et al.
Publicado: (2021)

CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS
por: Fanous, Hanna, et al.
Publicado: (2022)

3-Weekly Paclitaxel-Carboplatin With Radical Radiation for Stage III NSCLC – An Option During COVID-19 Pandemic
por: Wong, H.C.Y., et al.
Publicado: (2021)

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
por: Lim, Bora, et al.
Publicado: (2019)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
por: Xu, Na, et al.
Publicado: (2014)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0lv8kkak1u93v63e8m0mc10rgl